Hematological Malignancies

No WBRT 

Highly criticized: • Poor protocol adherence • Non-inferiority goal in OS not met • Insufficient toxicity evaluation • Overall poor results, sub-optimal chemo

• Neurotoxicity even with chemo alone (26%), with RT (49%) • Salvage improved survival, but carries high QOL/toxicity cost

35